Findings from the randomized EPIC17-VERONICA trial presented at Transcatheter Cardiovascular Therapeutics (TCT) 2026 showed that platelet function-guided de-escalation from potent P2Y12 inhibitors to clopidogrel did not significantly improve one-year clinical outcomes in patients with acute coronary syndrome (ACS).